Revenue segments as reported by the company.

Dialysis patient service revenues

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

General and administrative

Depreciation and amortization

Equity investment income (loss), net

Loss (gain) on changes in ownership interest, net

Goodwill impairment charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

DaVita

DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DaVita reports robust Q4 earnings, navigates challenges with strategic focus

DaVita's Q4 2022 performance reflects financial strength and operational improvements, supported by strategic initiatives and cost discipline.
While facing challenges in operational dynamics and market uncertainties, DaVita remains focused on growth opportunities and patient-centric care.
The company's outlook for 2023 shows a commitment to long-term success through innovation, efficiency, and resilience in a changing healthcare landscape.

DaVita reports strong Q1 earnings and innovation in kidney health

DaVita's Q1 2023 earnings call highlighted strong financial performance, operational efficiency, and a focus on patient care, positioning the company well for future growth and success.
While challenges such as limited operational details and potential labor management issues exist, DaVita's strengths in cost management, innovation, and patient-centric care present opportunities for sustained performance.
Overall, DaVita's positive momentum, revised financial outlook, and commitment to enhancing healthcare services indicate a promising trajectory for the company in the competitive healthcare landscape.

DaVita reports strong Q2 earnings, navigates CMS challenges effectively

DaVita's Q2 2023 performance reflects resilience amidst challenges, with a focus on innovation and operational efficiencies.
The company faces industry headwinds but remains committed to driving growth and enhancing patient care.
Analysts' questions highlighted key concerns and opportunities, showcasing DaVita's proactive approach to addressing industry dynamics.
Overall, DaVita's strategic focus on performance and stakeholder communication positions the company for continued success.

DaVita reports robust Q3 performance and eyes growth opportunities

DaVita's Q3 2023 Earnings Call highlighted strong financial results, operational priorities, and growth prospects. Despite challenges in managing drug impacts and market perception, the company remains focused on delivering quality care and driving shareholder value. Opportunities in CKD progression, shareholder returns, and IKC business improvement position DaVita for future success.

DaVita surpasses 2023 guidance, eyes growth and efficiency in 2024

DaVita's Q4 2023 Earnings Call showcased strong financial performance, exceeding guidance and highlighting a focus on efficiency and cost savings.
While facing challenges like legal proceedings and capacity utilization, DaVita remains optimistic about financial recovery and growth opportunities in 2024.
The company's successful Integrated Kidney Care program and commitment to driving operating performance position it well for continued success in the healthcare market.

DaVita reports robust Q1 earnings, eyes international expansion opportunities

DaVita's Q1 2024 performance reflects strong financial results and a strategic focus on kidney care solutions and international growth.
While challenges like the Change Healthcare outage were addressed, opportunities in expanding markets and enhancing patient care services are evident.
Management's commitment to quality care and sustainable growth positions DaVita well for continued success in the healthcare sector.

DaVita reports robust Q2 earnings, supports CMS proposal for growth

DaVita's Q2 2024 earnings call highlighted strong financial performance and strategic initiatives to drive growth.
While facing challenges in certain operational areas, the company's proactive stance on policy advocacy and financial guidance raise optimism.
Opportunities lie in optimizing operational metrics, managing costs effectively, and engaging stakeholders for sustained growth.

DaVita maintains financial course amidst challenges, eyes growth opportunities

DaVita's Q3 performance met expectations despite supply chain disruptions, with full-year guidance reaffirmed.
The company faces short-term challenges from hurricane impacts and regulatory uncertainties.
Opportunities lie in market changes and growth initiatives, though long-term guidance remains pending.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FedEx

Coca-Cola

Marsh & McLennan

SPDR S&P 500 ETF Trust

Teva Pharmaceutical

VeriSign

These Buffett stocks are suitable for a wide range of retail portfolios. Check out 7 of the Omaha Oracle's top stocks to buy for August.

The 7 Best Warren Buffett Stocks to Buy in August and Hold for Years

DaVita HealthCare (DVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DaVita HealthCare (DVA) Earnings Expected to Grow: Should You Buy?

DENVER, July 21, 2021 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss second quarter results on Tuesday, August 3, 2021, at 5:00 p.m. Eastern Time.

DaVita Inc. Schedules 2nd Quarter 2021 Investor Conference Call

Dialysis and kidney-care giant DaVita Inc. and its former chief executive were charged this week with conspiring with competing companies to not solicit one another's employees.

DaVita and its former CEO indicted, Justice Department charges illegal ‘no poaching' deals with rivals

Avangrid

Fiserv

These stocks check all the right boxes for the Oracle of Omaha.

3 Companies That Warren Buffett's Berkshire Hathaway Should Acquire

W. R. Grace & Co.

In September 2011, Warren Buffett (Trades, Portfolio)'s Berkshire Hathaway ( BRK.A , Financial) ( BRK.B , Financial) announced a new investment manager would join the business to work alongside the Oracle of Omaha, picking investments. This new manager's name was Ted Weschler.

A Look Back at Ted Weschler's Hedge Fund Holdings

Amedisys

DVA vs. AMED: Which Stock Is the Better Value Option?

DVA or AMED: Which Is the Better Value Stock Right Now?

East West Bancorp

Gartner

KLA-Tencor

Landstar System

Growth at a reasonable price or GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount.

5 GARP Stocks for a Winning Portfolio

American Express

Bank of America

Bank of New York Mellon

Warren Buffett's Berkshire Hathaway Inc. (NYSE: BRK-B) portfolio includes nearly four dozen stocks.

5 Stocks With Warren Buffett as the Largest Shareholder

Encompass Health

Select Medical Holdings

UnitedHealth Group

Healthcare stocks with long-term growth visibility can be important additions to investment portfolio when inflation runs high.

Save Your Portfolio From Inflation With Four Healthcare Stocks

AbbVie

Globe Life Inc

Kroger

According to the All-in-One Screener, a Premium feature of GuruFocus, four stocks in Berkshire Hathaway Inc.'s ( BRK.A , Financial)( BRK.B , Financial) equity portfolio that have high profitability and are trading at attractive price-to-free cash flow ratios are AbbVie Inc. ( ABBV , Financial), The Kroger Co. ( KR , Financial), DaVita Inc. ( DVA , Financial) and Globe Life Inc. ( GL , Financial).

4 Warren Buffett Holdings Trading at Low Price-to-Free Cash Flow Ratios

Apple

Kraft Heinz

Moody's

U.S. Bancorp

Verizon

Diversification isn't necessary if you know what you're doing, according to the Oracle of Omaha.

These 10 Stocks Make Up 85% of Warren Buffett's Portfolio

DaVita (DVA) and NKF collaborate to help kidney patients seeking a living donor, thereby improving health equity in kidney transplant process.

DaVita's (DVA) Deal to Aid Patients in Kidney Transplantation

Elanco Animal Health Inc

National Vision Hlds

Henry Schein

Phibro Animal Health

Here are some MedTech stocks with favorable PEG ratio, which are expected to provide gains in 2021.

5 Probable MedTech Winners Post-COVID on Discounted PEG

NEW YORK, June 10, 2021 /PRNewswire/ -- DaVita Kidney Care and the National Kidney Foundation (NKF) today announced their collaboration in launching an innovative, yearlong pilot aimed at improving health equity in kidney transplantation with a newly-developed program within NKF's THE BIG ASK: THE BIG GIVE platform. "Many people never find a living donor simply because they are afraid to ask," said Kevin Longino, CEO, National Kidney Foundation and a kidney transplant patient.

DaVita and the National Kidney Foundation Join Forces to Improve Health Equity in Kidney Transplantation

DENVER, June 2, 2021 /PRNewswire/ --  DaVita Kidney Care , a leading provider of home dialysis, launched virtual support groups through DaVita Care Connect®, a mobile health platform designed for home dialysis patients, to help create community and belonging for those treating at home. "Patients treating at home sometimes feel isolated and miss connecting with other people they feel they can relate to, which causes some patients to leave home treatment," said Dr. Martin Schreiber, chief medical officer for DaVita Home Modalities.

Virtual Support Groups Create Community for DaVita Home Dialysis Patients

Chemed

U.S. Physical Therapy

3 Stocks to Bank on Rebounding Outpatient Home Health Industry

DVA vs. AMED: Which Stock Should Value Investors Buy Now?

DENVER, May 13, 2021 /PRNewswire/ --  DaVita Kidney Care today announced that 60 of its nephrology nurses were honored with The DAISY Award for Extraordinary Nurses® during National Nurses Week. The award is part of the DAISY Foundation's mission to recognize the extraordinary, compassionate care that nurses provide to patients and families every day.

Extraordinary Nurses at DaVita Kidney Care Honored with DAISY Awards

DENVER, May 10, 2021 /PRNewswire/ --  DaVita Kidney Care  today announced the expansion of its home kidney care program to include the HomeChoice Claria Automated Peritoneal Dialysis (APD) system enabled by Sharesource remote patient monitoring from Baxter International Inc., a global innovator in renal care. This new technology further enhances DaVita's home dialysis program and is another important step forward to enable more patients to choose to treat their kidney failure at home.1 "With more than two decades of experience as the leading home dialysis provider, we know consistent communication between patients and care teams is crucial for building trust and confidence," said Dr. Martin Schreiber, chief medical officer for DaVita home modalities.

DaVita to Further Elevate its Home Dialysis Care Experience with New Baxter Technology

Century Communities

Herbalife

Repligen

Herbalife (HLF), DaVita (DVA), Apple (AAPL), Century Communities (CCS) & Repligen (RGEN) are the top stocks that flaunt attractive earnings growth at present.

5 of the Best Stocks to Buy Now for Striking Earnings Growth

DaVita's (DVA) net dialysis and related lab-patient service revenues rise in Q1.

DaVita (DVA) Q1 Earnings Beat Estimates, Revenues Miss Mark

DaVita's (DVA) CEO Javier Rodriguez on Q1 2021 Results - Earnings Call Transcript

DaVita HealthCare (DVA) delivered earnings and revenue surprises of 16.11% and -0.22%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

News for DaVita Stock (DVA)